Viewing data from:

FLUDROCORTISONE ACETATE

ANDA

FLUDROCORTISONE ACETATE | A040425 | BARR LABORATORIES INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Fludrocortisone Acetate (2023)

Total Spending

$13.0M

Total Claims

463,362

Beneficiaries

110,294

Avg Cost/Unit

$0.45

Spending Trend

$12.8M(2019)→$13.5M(2020)→$12.5M(2021)→$12.6M(2022)→$13.0M(2023)

YoY Change:+0.6%

5yr CAGR:-0.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs1 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

FARMABIOS SPAFLUDROCORTISONE ACETATE

DMF 141361999

TAPI NL BVFLUDROCORTISONE ACETATE

DMF 147031999

CURIA SPAIN SAUFLUDROCORTISONE ACETATE USP

DMF 210542007

NOVITIUM PHARMA LLCFLUDROCORTISONE ACETATE USP

DMF 349232020

HENAN LIHUA PHARMACEUTICAL CO LTDFLUDROCORTISONE ACETATE

DMF 363672021

MYLAN LABORATORIES LTDInactiveFLUDROCORTISONE ACETATE USP

DMF 229942009

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 0.1MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jan 21, 2003

No patent or exclusivity listings for this strength.